Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21826775 | 1.00 | PPM1D (0.36) | PPM1DNR1H2EPHX2ALDH1A1 | |
| SCHEMBL477666 | 1.00 | PPM1D (0.36) | PPM1DNR1H2EPHX2ALDH1A1 | |
| SCHEMBL13581959 | 0.87 | PPM1D (0.37) | PPM1DNR1H2 | |
| SCHEMBL13581958 | 0.87 | PPM1D (0.37) | PPM1DNR1H2 | |
| SCHEMBL1564591 | 0.84 | PPM1D (0.33) | PPM1D | |
| SCHEMBL20530900 | 0.84 | PPM1D (0.38) | PPM1D | |
| SCHEMBL20696426 | 0.84 | PPM1D (0.41) | PPM1D | |
| SCHEMBL20530884 | 0.84 | PPM1D (0.38) | PPM1D | |
| SCHEMBL1565719 | 0.84 | PPM1D (0.33) | PPM1D | |
| SCHEMBL1564593 | 0.84 | PPM1D (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-03 | — | — | US | disclosed |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | GENENTECH, INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-113195053-B | Amino acid compounds and methods of use | 普利安特治疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | PLIANT THERAPEUTICS INC (US) | 2024-08-15 | — | — | US | disclosed |
| CN-118201915-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2222165-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2219629-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009048936-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| EP-2038266-A2 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | Abbott Laboratories (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007140385-A2 | THIAZOLE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | PPM1D 3347/4885NR1H2 98/4885EPHX2 697/4885 |
| US-20250325552-A1 | SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLH | PPM1D 935/4885NR1H2 439/4885EPHX2 1342/4885 |
| US-20100249129-A1 | COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | PPM1D 2990/4885NR1H2 62/4885EPHX2 757/4885 |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | PPM1D 2972/4885NR1H2 232/4885EPHX2 597/4885 |
| US-20250213555-A1 | SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN1A, TRPA1 | PPM1D 1125/4885NR1H2 1530/4885EPHX2 4059/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | PPM1D 92/4885NR1H2 2741/4885EPHX2 4384/4885 |
| US-20240270742-A1 | SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS | ITGB6, ITGA1, ITGB1 | PPM1D 2802/4885NR1H2 1571/4885EPHX2 4541/4885 |
| US-20240383915-A1 | OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | OXA1L, GRIK4, GRIK5 | PPM1D 3821/4885NR1H2 702/4885EPHX2 1980/4885 |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | PPM1D 993/4885NR1H2 3180/4885EPHX2 3607/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | PPM1D 3075/4885NR1H2 243/4885EPHX2 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.